- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DISHMAN PHARMA - TEVA PHARMA (Israel)
DISHMAN PHARMA vs TEVA PHARMA (Israel) - Comparison Results
DISHMAN PHARMA 
Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 DISHMAN PHARMA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
TEVA PHARMA Dec-13 |
DISHMAN PHARMA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 2,860 | - | |
| Low | Rs | 129 | 2,484 | - | |
| Sales per share (Unadj.) | Rs | 197.8 | 1,641.2 | - | |
| Earnings per share (Unadj.) | Rs | 21.2 | 102.5 | - | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 235.2 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 89.75 | - | |
| Dividend yield (eoy) | % | 0.8 | 3.4 | 23.7% | |
| Book value per share (Unadj.) | Rs | 179.9 | 1,823.0 | - | |
| Shares outstanding (eoy) | m | 80.69 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 1.6 | 78.1% | |
| Avg P/E ratio | x | 11.9 | 26.1 | 45.5% | |
| P/CF ratio (eoy) | x | 7.2 | 11.4 | 63.8% | |
| Price / Book Value ratio | x | 1.4 | 1.5 | 95.4% | |
| Dividend payout | % | 9.4 | 87.5 | 10.8% | |
| Avg Mkt Cap | Rs m | 20,306 | 2,265,763 | 0.9% | |
| No. of employees | `000 | 0.8 | 44.9 | 1.8% | |
| Total wages/salary | Rs m | 5,355 | 0 | - | |
| Avg. sales/employee | Rs Th | 19,252.7 | 30,964.8 | 62.2% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
| Avg. net profit/employee | Rs Th | 2,064.1 | 1,934.3 | 106.7% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 1,391,712 | 1.1% | |
| Other income | Rs m | 265 | 0 | - | |
| Total revenues | Rs m | 16,226 | 1,391,712 | 1.2% | |
| Gross profit | Rs m | 4,103 | 381,121 | 1.1% | |
| Depreciation | Rs m | 1,091 | 112,493 | 1.0% | |
| Interest | Rs m | 944 | 27,335 | 3.5% | |
| Profit before tax | Rs m | 2,334 | 241,292 | 1.0% | |
| Minority Interest | Rs m | 0 | 1,096 | 0.0% | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -158,395 | 0.0% | |
| Tax | Rs m | 624 | -2,946 | -21.2% | |
| Profit after tax | Rs m | 1,711 | 86,939 | 2.0% | |
| Gross profit margin | % | 25.7 | 27.4 | 93.9% | |
| Effective tax rate | % | 26.7 | -1.2 | -2,188.8% | |
| Net profit margin | % | 10.7 | 6.2 | 171.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 939,957 | 1.2% | |
| Current liabilities | Rs m | 9,517 | 819,722 | 1.2% | |
| Net working cap to sales | % | 9.4 | 8.6 | 108.8% | |
| Current ratio | x | 1.2 | 1.1 | 101.0% | |
| Inventory Days | Days | 110 | 91 | 121.7% | |
| Debtors Days | Days | 35 | 96 | 36.3% | |
| Net fixed assets | Rs m | 16,304 | 454,564 | 3.6% | |
| Share capital | Rs m | 161 | 3,426 | 4.7% | |
| Net worth | Rs m | 14,516 | 1,545,928 | 0.9% | |
| Long term debt | Rs m | 4,189 | 711,613 | 0.6% | |
| Total assets | Rs m | 29,805 | 3,180,508 | 0.9% | |
| Interest coverage | x | 3.5 | 9.8 | 35.3% | |
| Debt to equity ratio | x | 0.3 | 0.5 | 62.7% | |
| Sales to assets ratio | x | 0.5 | 0.4 | 122.4% | |
| Return on assets | % | 8.9 | 3.6 | 248.0% | |
| Return on equity | % | 11.8 | 5.6 | 209.6% | |
| Return on capital | % | 17.5 | 4.9 | 355.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 221,767 | 1.3% | |
| From Investments | Rs m | -1,529 | -78,581 | 1.9% | |
| From Financial Activity | Rs m | -941 | -266,024 | 0.4% | |
| Net Cashflow | Rs m | 316 | -122,838 | -0.3% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 68.51 Rs / USD
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare DISHMAN PHARMA With: ELDER PHARMA ALEMBIC LTD UNICHEM LAB CADILA HEALTHCARE GSK PHARMA
|
| |
Today's Market
Sensex Ends 218 Points Lower; Tata Steel & Tata Motors Top Losers(Closing)
Indian share markets ended lower in the final hour of the trade. At the closing bell, the BSE Sensex finished lower by 218 points and the NSE Nifty finished down by 82 points.
Related Views On News
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
Has A Bank Ever Told You Its Deposits are Riskier than Stocks? These Should Have...(The 5 Minute Wrapup)
Jul 3, 2018Left on their own, the banks would possibly have to mark down the value of deposits by 90% to 100%.
The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)
Jul 4, 2018The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.
The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)
Jul 10, 2018If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...
New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)
Jul 6, 2018ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.
When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)
Jul 6, 2018Buy Companies that can fight all kinds of Pandas and Bears in the long run.
More|
| |
DISHMAN PHARMA SHARE PRICE
May 29, 2017 (Close)
TRACK DISHMAN PHARMA
- Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DISHMAN PHARMA
DISHMAN PHARMA 5-YR ANALYSIS
COMPARE DISHMAN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.